Search Results - "Kendler, D. L."

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies by Kendler, D. L., Chines, A., Brandi, M. L., Papapoulos, S., Lewiecki, E. M., Reginster, J-Y., Muñoz Torres, M., Wang, A., Bone, H. G.

“…Summary This post-hoc analysis queried whether women experiencing fracture on denosumab indicates inadequate treatment response or whether the risk of…”
Get full text

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate by Kendler, D. L., McClung, M. R., Freemantle, N., Lillestol, M., Moffett, A. H., Borenstein, J., Satram-Hoang, S., Yang, Y.-C., Kaur, P., Macarios, D., Siddhanti, S.

“…Summary In this study, 250 women with osteoporosis were randomized to 12 months with subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once…”
Get full text

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years by Ferrari, S., Adachi, J. D., Lippuner, K., Zapalowski, C., Miller, P. D., Reginster, J.-Y., Törring, O., Kendler, D. L., Daizadeh, N. S., Wang, A., O’Malley, C. D., Wagman, R. B., Libanati, C., Lewiecki, E. M.

“…Summary Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years,…”
Get full text

Population-based Canadian hip fracture rates with international comparisons by Leslie, W. D, O'Donnell, S, Lagacé, C, Walsh, P, Bancej, C, Jean, S, Siminoski, K, Kaiser, S, Kendler, D. L, Jaglal, S

“…Summary We identified hospitalizations throughout Canada during 2000-2005 in which the most responsible diagnosis was a proximal femoral fracture. Use of the…”
Get full text

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study by Silverman, S. L., Chines, A. A., Kendler, D. L., Kung, A. W. C., Teglbjærg, C. S., Felsenberg, D., Mairon, N., Constantine, G. D., Adachi, J. D.

“…Summary In this 2-year extension of a 3-year study, bazedoxifene showed sustained efficacy in preventing new vertebral fractures in postmenopausal women with…”
Get full text

Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry by Lewiecki, E. M., Gordon, C. M., Baim, S., Binkley, N., Bilezikian, J. P., Kendler, D. L., Hans, D. B., Silverman, S., Bishop, N. J., Leonard, M. B., Bianchi, M.-L., Kalkwarf, H. J., Langman, C. B., Plotkin, H., Rauch, F., Zemel, B. S.

“…The International Society for Clinical Densitometry (ISCD) conducts Position Development Conferences (PDCs) for the purpose of establishing standards and…”
Get full text

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis by Brown, J P, Kendler, D L, McClung, M R, Emkey, R D, Adachi, J D, Bolognese, M A, Li, Z, Balske, A, Lindsay, R

“…This study evaluated the efficacy and tolerability of risedronate once a week (35 mg and 50 mg) compared with risedronate 5 mg once daily in women with…”
Get full text

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass by Kendler, D. L, Bessette, L, Hill, C. D, Gold, D. T, Horne, R, Varon, S. F, Borenstein, J, Wang, H, Man, H.-S, Wagman, R. B, Siddhanti, S, Macarios, D, Bone, H. G

“…Summary The Preference and Satisfaction Questionnaire (PSQ) compares patient preference and satisfaction between a 6-month subcutaneous injection and weekly…”
Get full text

Diagnosis and management of bone fragility in diabetes: an emerging challenge by Ferrari, S.L., Abrahamsen, B., Napoli, N., Akesson, K., Chandran, M., Eastell, R., El-Hajj Fuleihan, G., Josse, R., Kendler, D.L., Kraenzlin, M., Suzuki, A., Pierroz, D.D., Schwartz, A.V., Leslie, W.D.

“…Fragility fractures are increasingly recognized as a complication of both type 1 and type 2 diabetes, with fracture risk that increases with disease duration…”
Get full text

Monitoring strontium ranelate therapy in patients with osteoporosis by Kendler, D. L, Adachi, J. D, Josse, R. G, Slosman, D. O

“…Purpose The purpose of this study was to review the monitoring of strontium ranelate osteoporosis therapy. Methods The method used in this study was…”
Get full text

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab by Kendler, D.L., Bone, H.G., Massari, F., Gielen, E., Palacios, S., Maddox, J., Yan, C., Yue, S., Dinavahi, R.V., Libanati, C., Grauer, A.

“…Summary Romosozumab is a therapy that stimulates bone formation and reduces bone resorption. In this study of postmenopausal women with low BMD, a second…”
Get full text

Special report on the official positions of the International Society for Clinical Densitometry by LEWIECKI, E. M, KENDLER, D. L, KIEBZAK, G. M, SCHMEER, P, PRINCE, R. L, FULEIHAN, G. El-Hajj, HANS, D

“…The International Society for Clinical Densitometry (ISCD) periodically holds Position Development Conferences (PDCs) for the purpose of establishing standards…”
Get full text

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate by RITTMASTER, R. S, BOLOGNESE, M, ETTINGER, M. P, HANLEY, D. A, HODSMAN, A. B, KENDLER, D. L, ROSEN, C. J

“…Treatment of osteoporosis with PTH causes a marked increase in vertebral bone mineral density (BMD). However, this effect is rapidly reversed when the…”
Get full text

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study by Papapoulos, S., Lippuner, K., Roux, C., Lin, C. J. F., Kendler, D. L., Lewiecki, E. M., Brandi, M. L., Czerwiński, E., Franek, E., Lakatos, P., Mautalen, C., Minisola, S., Reginster, J. Y., Jensen, S., Daizadeh, N. S., Wang, A., Gavin, M., Libanati, C., Wagman, R. B., Bone, H. G.

“…Summary The FREEDOM study and its Extension provide long-term information about the effects of denosumab for the treatment of postmenopausal osteoporosis…”
Get full text

Vertebral Fractures: Clinical Importance and Management by Kendler, D.L., MD, Bauer, D.C., MD, Davison, K.S., PhD, Dian, L., MBBS, Hanley, D.A., MD, Harris, S.T., MD, McClung, M.R., MD, Miller, P.D., MD, Schousboe, J.T., MD, Yuen, C.K., MD, MBA, Lewiecki, E.M., MD

“…Abstract Vertebral fractures are common and can result in acute and chronic pain, decreases in quality of life, and diminished lifespan. The identification of…”
Get full text

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women by Freemantle, N., Satram-Hoang, S., Tang, E.-T., Kaur, P., Macarios, D., Siddhanti, S., Borenstein, J., Kendler, D. L.

“…Summary The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and…”
Get full text

Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis by Kendler, D. L, Ringe, J. D, Ste-Marie, L. -G, Vrijens, B, Taylor, E. B, Delmas, P. D

“…Summary Two studies in postmenopausal women with osteoporosis provide information about the efficacy and safety of dosing oral risedronate 5 mg daily at a time…”
Get full text

Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis by Adachi, Jonathan D, Bensen, William G, Brown, Jacques, Hanley, David, Hodsman, Anthony, Josse, Robert, Kendler, David L, Lentle, Brian, Olszynski, Wojciech, Ste.-Marie, Louis-George, Tenenhouse, Alan, Chines, Arkadi A, Jovaisas, Algis, Sturtridge, William C, Anastassiades, Tassos P, Hanly, John G, Pope, Janet E, Dias, Reginald, Horowitz, Zebulun D, Pack, Simon

“…High-dose oral corticosteroid therapy is given to patients with a variety of medical conditions. Although often effective, corticosteroids commonly cause…”
Get full text

Bone management in hematologic stem cell transplant recipients by Kendler, D. L., Body, J. J., Brandi, M. L., Broady, R., Cannata-Andia, J., Cannata-Ortiz, M. J., El Maghraoui, A., Guglielmi, G., Hadji, P., Pierroz, D. D., de Villiers, T. J., Rizzoli, R., Ebeling, P. R.

“…Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for patients with some malignant and non-malignant…”
Get full text

Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation by Hiligsmann, M., Reginster, J.-Y., Tosteson, A.N.A., Bukata, S.V., Saag, K.G., Gold, D.T., Halbout, P., Jiwa, F., Lewiecki, E.M., Pinto, D., Adachi, J.D., Al-Daghri, N., Bruyère, O., Chandran, M., Cooper, C., Harvey, N.C., Einhorn, T.A., Kanis, J.A., Kendler, D.L., Messina, O.D., Rizzoli, R., Si, L., Silverman, S.

“…Summary Economic evaluations are increasingly used to assess the value of health interventions, but variable quality and heterogeneity limit the use of these…”
Get full text